This activity is designed to inform physicians about the adverse events observed when treating patients with targeted therapies as well as immunotherapies such as checkpoint inhibitors.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists, dermatologists, pulmonary care specialists, endocrinologists, gastroenterologists, primary care physicians, nurses, and advanced practitioners who treat and/or manage cancer patients that are being treated with targeted therapies or checkpoint inhibitors. Surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the management of adverse events associated with targeted therapies and checkpoint inhibitors are also invited to participate.
After participating in this CME/CE activity, learners should be better prepared to:
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Biotechnology Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, OncoPlex Diagnostics, Merck, and Novartis.
Mario E. Lacouture, MD
Director, Oncodermatology Program
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant Research/Support: Berg, Bristol-Myers Squibb, Genentech
The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.
It is the policy of PER® to ensure fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This continuing medical and nursing education activity may or may not discuss investigational, unapproved or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, and management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC. Contact information for questions about the activity:
Physicians' Education Resource®, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Phone: (888) 949-0045
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY